Table 3.
Sensitivity analyses for associations between isoniazid preventive therapy and mortality using various scenarios
| # death/pyrs | Rate per 100 pyrs | Unadjusted HR | Adjusted HR* (95% CI) | ||
|---|---|---|---|---|---|
| Restricted to those with no previous tuberculosis (N=3036) | No IPT | 209/1872 | 11.16 | 1 | 1 (P=0.003) |
| IPT | 32/843 | 3.80 | 0.35 | 0.51(0.32 – 0.81) | |
| Restricted to those with no tuberculosis symptoms at ART initiation (N=1923) | No IPT | 66/1011 | 5.99 | 1 | 1 (P=0.08) |
| IPT | 15/683 | 2.19 | 0.37 | 0.48 (0.24 – 0.96) | |
| Including all those medically boarded as deaths (N=3270) | No IPT | 310/2047 | 15.14 | 1 | 1 (P=0.11) |
| IPT | 48/863 | 5.56 | 0.37 | 0.66 (0.45 – 0.97) | |
| Restricted to no previous TB and no TB symptoms at initiation (n=1795) | No IPT | 61/1007 | 6.06 | 1 | 1 (P=0.05) |
| IPT | 15/699 | 2.24 | 0.37 | 0.44 (0.22 – 0.89) |
IPT: isoniazid preventive therapy; ART: antiretroviral therapy
*
Adjusted for age group, baseline WHO stage baseline CD4 count, year started on ART and individual company